NEURELIS INC
PharmaNEURELIS INC is a pharmaceutical company focused on Neurology. Key products include VALTOCO.
Upcoming FDA Decisions
Full Calendar →NEURELIS INC's Key Drugs
NEURELIS INC's core commercial portfolio centers on VALTOCO, spanning Neurology — its most strategically important drugs approved in the last 15 years.
NEURELIS INC's Recent FDA Approvals
New NDA/BLA approvals for NEURELIS INC over the last two years — novel drugs only, excluding generics and label supplements.
NEURELIS INC's Therapeutic Areas
NEURELIS INC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NEURELIS INC's Top Competitors
NEURELIS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NEURELIS INC Pipeline Snapshot
NEURELIS INC has 3 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VALTOCO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-01-10
- Latest
- 2025-06-14
- Applications
- 1